News for Theriva Biologics Inc Stock (TOVX)

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

GlobeNewsWire • 10/16/24

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

GlobeNewsWire • 09/27/24

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

GlobeNewsWire • 09/23/24

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

GlobeNewsWire • 09/16/24

Theriva Biologics Announces Reverse Stock Split

GlobeNewsWire • 08/16/24

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

GlobeNewsWire • 07/31/24

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

GlobeNewsWire • 05/23/24

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

GlobeNewsWire • 05/14/24

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

GlobeNewsWire • 05/07/24

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

GlobeNewsWire • 04/25/24

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

GlobeNewsWire • 04/23/24

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

GlobeNewsWire • 04/22/24

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

GlobeNewsWire • 04/08/24

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

Seeking Alpha • 03/25/24

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

GlobeNewsWire • 03/25/24

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

GlobeNewsWire • 03/19/24

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

GlobeNewsWire • 03/11/24

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 02/07/24

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

GlobeNewsWire • 01/16/24

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/17/23

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

GlobeNewsWire • 11/13/23

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

GlobeNewsWire • 11/06/23

Theriva™ Biologics to Participate in the BIO-Europe Conference

GlobeNewsWire • 11/02/23

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

GlobeNewsWire • 11/02/23

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

GlobeNewsWire • 10/23/23